Response to: ‘Tofacitinib for the treatment of polyarteritis nodosa: a literature review’. Correspondence on ‘Tofacitinib for polyarteritis nodosa: a tailored therapy’ by Rimaret al
Open Access
- 9 September 2020
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 81 (10), e205
- https://doi.org/10.1136/annrheumdis-2020-218790
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Tocilizumab for the treatment of polyarteritis nodosa: a systematic literature review. Correspondence on ‘Tofacitinib for polyarteritis nodosa: a tailored therapy’ by Rimaret alAnnals Of The Rheumatic Diseases, 2020
- Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: replyRheumatology, 2020
- Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related diseaseAnnals Of The Rheumatic Diseases, 2020
- Usefulness of vasculitis biomarkers in the era of the personalized medicineAutoimmunity Reviews, 2020
- Infliximab for the treatment of refractory polyarteritis nodosaClinical Rheumatology, 2019
- Vasculitis Pathogenesis: Can We Talk About Precision Medicine?Frontiers in Immunology, 2018
- Trial of Tocilizumab in Giant-Cell ArteritisThe New England Journal of Medicine, 2017
- Tofacitinib for polyarteritis nodosa: a tailored therapyAnnals Of The Rheumatic Diseases, 2016